The Lancet: First human trial of COVID-19 vaccine finds it is safe and induces rapid immune response

The first COVID-19 vaccine to reach phase 1 clinical trial has been found to be safe, well-tolerated, and able to generate an immune response against SARS-CoV-2 in humans, according to new research published in The Lancet. The open-label trial in 108 healthy adults demonstrates promising results after 28 days–the final results will be evaluated in…

The Lancet: No evidence of benefit for chloroquine and hydroxychloroquine in COVID-19 patients

A large observational study suggests that treatment with the antimalarial drug chloroquine or its analogue hydroxychloroquine (taken with or without the antibiotics azithromycin or clarithromycin) offers no benefit for patients with COVID-19. The study analysed data from nearly 15,000 patients with COVID-19 receiving a combination of any of the four drug regimens and 81,000 controls.…

£7 million government investment in Patient Recruitment Centres for commercial clinical research

NHS patients will benefit from easier access to clinical research opportunities, following a £7 million government investment to launch five new regional Patient Recruitment Centres (PRCs) across England. The five new centres are distributed across the country to provide opportunities for patients in regions across England who may not previously have been able to take…

No improvement in death rate for COVID-19 patients who received hydroxychloroquine

Boston, MA — A research team led by investigators from Brigham and Women’s Hospital has evaluated real-world evidence related to outcomes for COVID-19 patients who were treated with hydroxychloroquine or chloroquine analogues (with or without a macrolide). Investigators found no evidence that either drug regimen reduced the death rate among patients. Patients treated with hydroxychloroquine…

When developing vaccines against COVID-19, ‘fast is slow, and slow is fast’

Bypassing clinical trials for a potential SARS-CoV-2 vaccine would be “catastrophic,” says Science Advances deputy editor Douglas Green in this Editorial. Instead, it’s vital to take time to ensure any vaccine candidate’s safety and investigate potential adverse effects, he says. A vaccine able to trigger strong neutralizing antibody responses in clinical tests will still not…

Large-scale analysis of protein arginine methylation by mass spectrometry

Methylation (namely addition of a methyl group) of arginine amino acid residues of proteins is a post-translational modification (PTM) catalyzed by a family of nine enzymes called Protein Arginine Methyl-Transferases (PRMTs). PRMTs have been gaining increasing attention in the scientific landscape due their role in several essential physiological processes and implication in various diseases, including…

Introducing TVT connect

NEW YORK – May 22, 2020 – The Cardiovascular Research Foundation (CRF) has announced that TVT Connect, the Structural Heart Summit, will take place online June 18-28, 2020. TVT Connect features expertly developed series, late-breaking clinical science, challenging cases, industry-sponsored sessions, and connection to a community of thought leaders from across the globe. “We transformed…